A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers
The goal of this trial is to test the safety and efficacy of an innovative combination aimed to more profoundly inhibit ERK signaling in tumors.
Advanced BRAF Mutant Cancers
DRUG: Binimetinib|DRUG: Encorafenib
Dose-limiting Toxicities (DLTs), National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 5,, 1 year|Objective Response Rate (Phase II), Per RECIST Version 1.1, 1 year
The goal of this trial is to test the safety and efficacy of an innovative combination aimed to more profoundly inhibit ERK signaling in tumors.